_CDMO_Market_1.jpg)
The Lipid Nanoparticles (LNPs) CDMO Market Size is valued at 161.7 Million in 2022 and is predicted to reach 450.2 Million by the year 2030 at a 13.80 % CAGR during the forecast period for 2022-2030.
In recent years, a remarkable advancement in nanoscale drug delivery methods has been made. A novel nano-colloidal system for drug administration has emerged in the form of solid lipid nanoparticles (SLNs). Due to the lipid matrix's biocompatibility, lipid nanoparticles (LNPs) are frequently used in drug delivery. The most promising method for oral delivery is solid lipid nanoparticles (SLN), which have improved solubility, stability, permeability, and bioavailability while posing fewer side effects than standard dose formulations. Increasing clinical demand for small molecules is favouring the business of contract manufacturing service providers.
The most advanced non-viral therapeutically authorised mRNA delivery technologies are lipid nanoparticles (LNPs). The ability of an mRNA vaccine to deliver a therapeutic outcome is related to the capacity of LNPs to provide the nucleic acid intact into cells. For Instance, in 2021, WACKER and CordenPharma signed a development collaboration in the field of Lipid Nanoparticle formulation. The two companies reported that they intend to jointly develop know-how and methods for manufacturing Lipid Nanoparticles (LNPs) to meet the growing market demand.
Major driving factors of the Lipid Nanoparticles (LNPs) CDMO market are the surging medical applications of nanoparticles, increasing investments by key players in lipid nanoparticles to develop promising drug therapies, rising cases of chronic diseases, an increasing aging population, and a growing number of health-conscious people. The rising chronic and infectious disease cases have increased pharmaceutical companies' product manufacturing burden. Hence, biopharma companies started to opt for contract manufacturing services to save time and handle lipid/nanoparticle production operations, which is expected to create business growth opportunities for the market over the forecast years. However, the high cost of outsourced services, lack of necessary infrastructures, need for specialized expertise for nanoparticle production, and complex manufacturing procedures may restrain the market growth during the estimated timeframe.
Market Segmentation
The Lipid Nanoparticles (LNPs) CDMO market is segmented based on product, the scale of operation, end-users, and region. The product segment comprises mRNA , Plasmid DNA (pDNA), siRNA, saRNA, microRNA, and Others. By scale of operation, the market is classified into preclinical scale operations, clinical scale operations, and commercial-scale operations. The market is grouped into Pharmaceutical Companies, Academic Research Institute, and Diagnostic Laboratories. Pharmaceutical companies are projected to hold a significant market share over the forecast years owing to the high prevalence of chronic diseases and rising innovative drug developments. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
North America is estimated to witness rapid growth in the next few years due to the increasing awareness about the applications of nanoparticles, rising government investments in the R&D of nanoparticle products, and the high prevalence of chronic diseases.
Competitive Landscape
Some major key players in the The Lipid Nanoparticles (LNPs) CDMO Market:
- Genevant Sciences
- Lonza Group AG
- Rentschler Biopharma
- Nitto Denko Avecia
- Evonik
- Laboratorios Farmacéuticos Rovi, S.A.
- Samsung Biologics
- Thermo Fisher Scientific
- Sartorius AG (BIA Separations)
- AGC Biologics
- Hanmi Pharmaceutical
- BioCina Pty Ltd.
- Catalent, Inc
- Corden Pharma GmbH,
- eTheRNA,
- Polypeptide Therapeutic Solutions(PTS),
- FUJIFILM Corporation,
- ST Pharm Co Ltd,
- Exalead (Merck KGaA),
- Avanti Polar Lipids, Inc. (Croda International Plc.),
- Emergent CDMO,
- Esco Aster Pte Ltd,
- ernal Biosciences,
- Arranta Bio,
- Phosphorex Inc,
- Polymun Scientific Immunbiologische Forschung GmbH,
- BIOVECTRA
- Vernal Biosciences
- Helix Biotech
The Lipid Nanoparticles (LNPs) CDMO Market Report Scope
|
Report Attribute |
Specifications |
|
Market size value in 2022 |
USD 161.7 Million |
|
Revenue forecast in 2030 |
USD 450.2 Million |
|
Growth rate CAGR |
CAGR of 13.80 % from 2022 to 2030 |
|
Quantitative units |
Representation of revenue in US$ Million and CAGR from 2022 to 2030 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2022-2030 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments covered |
Product, Scale of Operation, End-User |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Corden Pharma GmbH, eTheRNA, Polypeptide Therapeutic Solutions(PTS), FUJIFILM Corporation, ST Pharm Co Ltd, Exalead (Merck KGaA), Avanti Polar Lipids, Inc. (Croda International Plc.), Emergent CDMO, Esco Aster Pte Ltd, ernal Biosciences, Arranta Bio, Phosphorex Inc, Polymun Scientific Immunbiologische Forschung GmbH, BIOVECTRA, Vernal Biosciences, Helix Biotech |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
